AVM Biotechnology is a clinical-stage company, founded by Theresa Deisher, Ph.D. The company is developing AVM0703, a proprietary and innovative therapeutic option for cancer and autoimmune diseases. AVM’s passion is to deliver drugs that are effective, safe, work rapidly and are accessible.
Dr. Deisher, with over 30 years of successful pharmaceutical research and development experience and holding over 47 patents, leads a team of scientists dedicated to changing what a life altering or life threatening diagnosis means to patients and their loved ones. She is guided by her personal philosophy that side effects from treatments should never be worse than the diseases themselves.